rss
Br J Ophthalmol 2008;92:916-921 doi:10.1136/bjo.2007.131037
  • Original Article
    • Clinical science

Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema?

  1. J H Chang1,2,3,
  2. P McCluskey2,3,
  3. T Missotten1,
  4. P Ferrante1,
  5. B Jalaludin4,
  6. S Lightman1
  1. 1
    Department of Clinical Ophthalmology, Institute of Ophthalmology, Moorfields Eye Hospital, City Road, London, UK
  2. 2
    Department of Ophthalmology, Liverpool Hospital, Sydney, Australia
  3. 3
    Laboratory of Ocular Immunology, School of Medical Sciences, University of NSW, Sydney, Australia
  4. 4
    Centre for Research, Evidence Management and Surveillance, Liverpool Hospital Sydney Australia
  1. Professor P McCluskey, Department of Ophthalmology, Liverpool Hospital, Locked Bag 7103, Liverpool BC NSW 1871, Australia; peter.mccluskey2{at}sswahs.nsw.gov.au
  • Accepted 9 April 2008
  • Published Online First 6 May 2008

Abstract

Aim: A retrospective comparative case series was studied to determine whether the use of prostaglandin (PG) analogues to treat raised intraocular pressure (IOP) in patients with uveitis resulted in an increase in the frequency of anterior uveitis or cystoid macular oedema (CMO).

Methods: 163 eyes of 84 consecutive patients with uveitis and raised IOP treated with a PG analogue at two tertiary referral uveitis clinics were identified over a 3-month period. Control eyes were selected as those uveitic eyes of the same patients, which were treated with topical IOP-lowering agent(s) other than a PG analogue. Pretreatment IOP was compared with the mean IOP during PG analogue treatment. The frequency of anterior uveitis and CMO during PG analogue treatment was compared with the frequency of these complications in the control eyes during non-PG IOP-lowering treatment.

Results: Significant IOP reductions were observed during PG analogue treatment. There was no significant difference in the frequency of anterior uveitis in those eyes treated with PG analogues and those treated with non-PG agents (p = 0.87, Fisher exact test). None of the 69 uveitic eyes without a previous history of CMO developed this complication. There was no increase in the frequency of visually significant CMO during PG treatment compared with that during non-PG treatment (p = 0.19, Fisher exact test).

Conclusion: This study demonstrates that PG analogues are potent topical medications for lowering raised IOP in patients with uveitis and are not associated with increased risk of CMO or anterior uveitis.

Footnotes

  • Funding: NH&MRC of Australia Postgraduate Medical Research Scholarship (JHC, Grant No 222928), NH&MRC Travelling Award (JHC, Grant No 351030)

  • Competing interests: None.

  • Ethics approval: Appropriate ethics committee approvals for this study were obtained.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2007.131037v1
    2. 92/7/916 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.